Discovery of 4-Methyl Quinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease and its molecular pathogenesis remains poorly understood. Recently, emerging evidence demonstrates that the PI3K signaling transduction pathway is linked to the pathology of IPF. In this work, we rationally designed a new series of 4-methyl quinazoline derivatives as highly potent PI3K inhibitors which significantly suppress the phosphorylation of the main PI3K downstream effectors and displays marked anti-proliferative activity in mouse MLg2908 lung fibroblasts. In a bleomycin-induced mouse pulmonary fibrosis model, compound 5d from the series improved mouse lung function and slowed the progression of pulmonary fibrosis. Overall, this work promises a therapeutic potential for PI3K inhibitors to treat IPF.

[1]  M. Perry,et al.  Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. , 2019, Journal of medicinal chemistry.

[2]  Michael J. Stocks,et al.  Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. , 2019, Journal of medicinal chemistry.

[3]  R. Chambers,et al.  A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis , 2019, European Respiratory Journal.

[4]  Shaney Barratt,et al.  Idiopathic Pulmonary Fibrosis (IPF): An Overview , 2018, Journal of clinical medicine.

[5]  Xiaoguang Chen,et al.  Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. , 2018, Journal of medicinal chemistry.

[6]  J. Liou,et al.  Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. , 2017, Journal of medicinal chemistry.

[7]  S. Ikeda,et al.  Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. , 2016, JAMA oncology.

[8]  O. Eickelberg,et al.  Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition , 2016, Thorax.

[9]  Rachel C Chambers,et al.  Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF , 2016, Thorax.

[10]  P. Liu,et al.  Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors. , 2015, ACS medicinal chemistry letters.

[11]  G. Rossi,et al.  Idiopathic pulmonary fibrosis: An update , 2015, Annals of medicine.

[12]  A. Ray,et al.  Emerging therapeutic interventions for idiopathic pulmonary fibrosis , 2014, Expert opinion on investigational drugs.

[13]  H. Collard,et al.  Pathogenesis of idiopathic pulmonary fibrosis. , 2014, Annual review of pathology.

[14]  Carlo Vancheri,et al.  PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition , 2013, Laboratory Investigation.

[15]  S. Planey,et al.  The influence of lipophilicity in drug discovery and design , 2012, Expert opinion on drug discovery.

[16]  C. Vancheri,et al.  Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms , 2011, PloS one.

[17]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[18]  J. Whitsett,et al.  Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis. , 2010, The American journal of pathology.

[19]  Kaushik Raha,et al.  Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. , 2010, ACS medicinal chemistry letters.

[20]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[21]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[22]  K. Chida,et al.  Cumulative incidence of and predictive factors for lung cancer in IPF , 2009, Respirology.

[23]  R. Nho,et al.  Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis , 2008, The Journal of experimental medicine.

[24]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[25]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[26]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.